<DOC>
	<DOCNO>NCT00400296</DOCNO>
	<brief_summary>This single arm study determine maximum tolerate dose , recommend dose development , R547 , patient advance solid tumor . Groups patient receive ascend dos R547 weekly intravenous infusion administer ) 90 minute b ) 180 minute , day 1 8 21 day cycle . In absence dose-limiting toxicity follow start dose , incremental dose-escalations allow subsequent cohort patient maximum tolerate dose reach . The anticipated time study treatment disease progression dose-limiting toxicity , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study R547 Patients With Advanced Solid Tumors .</brief_title>
	<detailed_description />
	<criteria>adult patient , &gt; =18 year age ; locally advance metastatic solid tumor ; measurable evaluable disease . prior chemotherapy , radiotherapy immunotherapy within 3 week start study ; prior history CNS metastases disease progression ; patient take strong inhibitor and/or inducer CYP3A4 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>